Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

被引：78

作者：

Kang, Jee Hye ^{[1
,2
]}

Bluestone, Jeffrey A. ^{[1
,2
,3
]}

Young, Arabella ^{[1
,2
,4
]}

机构：

[1] Univ Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA

[3] Sonoma Biotherapeut, San Francisco, CA USA

[4] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

来源：

TRENDS IN IMMUNOLOGY | 2021年 / 42卷 / 04期

基金：

英国医学研究理事会; 美国国家卫生研究院;

关键词：

ADVERSE EVENTS; 1ST-LINE TREATMENT; ADVANCED MELANOMA; CLINICAL IMPACT; INDUCED COLITIS; TH17; CELLS; ANTI-TNF; CANCER; IPILIMUMAB; NIVOLUMAB;

D O I：

10.1016/j.it.2021.02.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatmentinduced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity.

引用

页码：293 / 311

页数：19

共 121 条

[61] Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey [J].

Lesage, Candice ;

Longvert, Christine ;

Prey, Sorilla ;

Maanaoui, Sarah ;

Dreno, Brigitte ;

Machet, Laurent ;

Zehou, Ouidad ;

Kramkimel, Nora ;

Jeudy, Geraldine ;

Skowron, Francois ;

Aubin, Francois ;

Visseaux, Laetitia ;

Mansard, Sandrine ;

Dereure, Olivier ;

Lesage, Francois-Xavier ;

Guillot, Bernard .

JOURNAL OF IMMUNOTHERAPY, 2019, 42 (05) :175-179

[62] Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy [J].

Lim, Su Y. ;

Lee, Jenny H. ;

Gide, Tuba N. ;

Menzies, Alexander M. ;

Guminski, Alexander ;

Carlino, Matteo S. ;

Breen, Edmond J. ;

Yang, Jean Y. H. ;

Ghazanfar, Shila ;

Kefford, Richard F. ;

Scolyer, Richard A. ;

Long, Georgina V. ;

Rizos, Helen .

CLINICAL CANCER RESEARCH, 2019, 25 (05) :1557-1563

[63] Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer [J].

Liu, Jing ;

Blake, Stephen J. ;

Harjunpaa, Heidi ;

Fairfax, Kirsten A. ;

Yong, Michelle C. R. ;

Allen, Stacey ;

Kohrt, Holbrook E. ;

Takeda, Kazuyoshi ;

Smyth, Mark J. ;

Teng, Michele W. L. .

CANCER RESEARCH, 2016, 76 (18) :5288-5301

[64] Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy [J].

Luoma, Adrienne M. ;

Suo, Shengbao ;

Williams, Hannah L. ;

Sharova, Tatyana ;

Sullivan, Keri ;

Manos, Michael ;

Bowling, Peter ;

Hodi, F. Stephen ;

Rahma, Osama ;

Sullivan, Ryan J. ;

Boland, Genevieve M. ;

Nowak, Jonathan A. ;

Dougan, Stephanie K. ;

Dougan, Michael ;

Yuan, Guo-Cheng ;

Wucherpfennig, Kai W. .

CELL, 2020, 182 (03) :655-+

[65] Interleukin-23 engineering improves CAR T cell function in solid tumors [J].

Ma, Xingcong ;

Shou, Peishun ;

Smith, Christof ;

Chen, Yuhui ;

Du, Hongwei ;

Sun, Chuang ;

Kren, Nancy Porterfield ;

Michaud, Daniel ;

Ahn, Sarah ;

Vincent, Benjamin ;

Savoldo, Barbara ;

Pylayeva-Gupta, Yuliya ;

Zhang, Shuqun ;

Dotti, Gianpietro ;

Xu, Yang .

NATURE BIOTECHNOLOGY, 2020, 38 (04) :448-+

[66] Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity [J].

Mahalingam, Devalingam ;

Wang, Judy S. ;

Hamilton, Erika P. ;

Sarantopoulos, John ;

Nemunaitis, John ;

Weems, Garry ;

Carter, Laura ;

Hu, Xiao ;

Schreeder, Marshall ;

Wilkins, H. Jeffrey .

CLINICAL CANCER RESEARCH, 2019, 25 (12) :3508-3516

[67] Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody [J].

Maher, V. Ellen ;

Fernandes, Laura L. ;

Weinstock, Chana ;

Tang, Shenghui ;

Agarwal, Sundeep ;

Brave, Michael ;

Ning, Yang-min ;

Singh, Harpreet ;

Suzman, Daniel ;

Xu, James ;

Goldberg, Kirsten B. ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Theoret, Marc ;

Beaver, Julia A. ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2730-+

[68] T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity [J].

Martin-Orozco, Natalia ;

Muranski, Pawel ;

Chung, Yeonseok ;

Yang, Xuexian O. ;

Yamazaki, Tomohide ;

Lu, Sijie ;

Hwu, Patrick ;

Restifo, Nicholas P. ;

Overwijk, Willem W. ;

Dong, Chen .

IMMUNITY, 2009, 31 (05) :787-798

[69] Cytokines in rheumatoid arthritis - shaping the immunological landscape [J].

McInnes, Iain B. ;

Buckley, Christopher D. ;

Isaacs, John D. .

NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (01) :63-68

[70] Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System [J].

Mehta, Vikas ;

Goel, Sanjay ;

Kabarriti, Rafi ;

Cole, Daniel ;

Goldfinger, Mendel ;

Acuna-Villaorduna, Ana ;

Pradhan, Kith ;

Thota, Raja ;

Reissman, Stan ;

Sparano, Joseph A. ;

Gartrell, Benjamin A. ;

Smith, Richard, V ;

Ohri, Nitin ;

Garg, Madhur ;

Racine, Andrew D. ;

Kalnicki, Shalom ;

Perez-Soler, Roman ;

Halmos, Balazs ;

Verma, Amit .

CANCER DISCOVERY, 2020, 10 (07) :935-941

← 2 3 4 5 6 7 8 9 10 11 →